RARExCAN: Establishing rare cancer and exceptional responders network in India to accelerate translational research.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Axis Bank
- 入组人数
- 8,000
- 试验地点
- 2
- 主要终点
- 1. Establishing a complete clinical database for rare cancers and exceptional responders.
研究概览
简要总结
Rare cancers are uncommon individually but collectively contribute to a significant portion of cancer cases and deaths worldwide. These cancers are challenging to diagnose and treat because of delays in diagnosis, misdiagnosis, limited research, and lack of standardized treatment options. This project aims to address these issues by creating a collaborative network of cancer centers across India, linked through a "hub and spoke" model.The project will focus on improving diagnosis by enabling expert review of pathology reports and advanced molecular testing at specialized centers (hubs). It will establish a shared database to collect detailed clinical and biological information on patients with rare cancers and those who respond exceptionally well to treatment. This will help researchers understand the unique biology of these cancers and develop more effective, personalized treatments.The network will also create a biobank to store tumor and normal tissue samples for future research and support clinical trials tailored to rare cancers. Additionally, expert multidisciplinary teams will provide guidance on treatment plans for complex cases through virtual tumor boards/MDT meetings. Training programs, educational resources, and recorded sessions will help build expertise among healthcare professionals nationwide.By streamlining diagnosis, improving treatment strategies, and fostering research collaborations, the project aims to significantly improve outcomes for patients with rare cancers, advance scientific understanding, and build capacity for managing these cancers effectively in India.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 0.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •Any patient that fits the rare cancer definition as per the protocol which is, Rare Cancers will be defined as those with incidence of less than 6 cases per 100,000, rare pathological subtypes of common cancers,pediatric cancers,hematological cancers and unusual site or age at presentation.
- •Willing to give consent.
排除标准
- •Not willing to give consent.
- •If received any prior treatment.
结局指标
主要结局
1. Establishing a complete clinical database for rare cancers and exceptional responders.
时间窗: 1. Continuous process, At the end of 5 years, the data will be analyzed to understand the prevalence and pattern of rare cancers in the network along with treatment outcomes. | 2. All the biopsy/surgical specimens at the hub/spokes will be collected over 10 years. | 3. The data entered in the clinical database linked to the virtual biobank will be analyzed at 3, 5 and 10 years from the start of the project. | 4. The follow up of the cases discussed will be provided at periodic intervals (every 6 months) as a consolidated report. The database will be updated every 6 months for the treatment plan, treatment given, response and the outcome.
2. Establishing biorepository of all clinically annotated rare cancers and exceptional responders for exploration of biological basis.
时间窗: 1. Continuous process, At the end of 5 years, the data will be analyzed to understand the prevalence and pattern of rare cancers in the network along with treatment outcomes. | 2. All the biopsy/surgical specimens at the hub/spokes will be collected over 10 years. | 3. The data entered in the clinical database linked to the virtual biobank will be analyzed at 3, 5 and 10 years from the start of the project. | 4. The follow up of the cases discussed will be provided at periodic intervals (every 6 months) as a consolidated report. The database will be updated every 6 months for the treatment plan, treatment given, response and the outcome.
3.Analyzing patterns of care and outcomes of rare cancers and exceptional responders versus others.
时间窗: 1. Continuous process, At the end of 5 years, the data will be analyzed to understand the prevalence and pattern of rare cancers in the network along with treatment outcomes. | 2. All the biopsy/surgical specimens at the hub/spokes will be collected over 10 years. | 3. The data entered in the clinical database linked to the virtual biobank will be analyzed at 3, 5 and 10 years from the start of the project. | 4. The follow up of the cases discussed will be provided at periodic intervals (every 6 months) as a consolidated report. The database will be updated every 6 months for the treatment plan, treatment given, response and the outcome.
4.Improving the outcomes of rare cancers through delivery of uniform care
时间窗: 1. Continuous process, At the end of 5 years, the data will be analyzed to understand the prevalence and pattern of rare cancers in the network along with treatment outcomes. | 2. All the biopsy/surgical specimens at the hub/spokes will be collected over 10 years. | 3. The data entered in the clinical database linked to the virtual biobank will be analyzed at 3, 5 and 10 years from the start of the project. | 4. The follow up of the cases discussed will be provided at periodic intervals (every 6 months) as a consolidated report. The database will be updated every 6 months for the treatment plan, treatment given, response and the outcome.
次要结局
- Evaluate novel study designs for conduct of clinical trials in rare cancers
研究者
Dr CS Pramesh
Tata Memorial Hospital,Mumbai